Improving T cell therapy manufacturing processes with automation and scalability

Live30 webinars are thirty minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format.

The field of cell therapy is in its early stages but has already demonstrated immense promise. In order to realize the potential of these revolutionary treatments, however, many challenges need to be addressed, most notably safety and cost. Two universally accepted approaches to mitigating safety and cost issues are automation and scalability. The closed and automated CTS DynaCellect isolation process achieves >90% isolation efficiency of target cells with ~95% purity with no effect on cell viability, and the automated bead removal process is fast and efficient and currently results in >85% target cell recovery.

Moreover, the CTS DynaCellect is highly scalable and able to process up to 1 liter (or 10 billion target cells) per isolation reaction with a throughput time of =90 minutes, and bead removal is achieved through a continuous flow to ensure rapid processing of all volumes characteristic of autologous and allogenic workflows.Following the upstream cellular processing, stirred tank bioreactors have been identified as the most effective, scalable, and flexible, closed and automated vessels for expansion of cell therapies. They possess superior control over the culture characteristics, such as mixing, gassing and liquid exchange. These capabilities have improved yields compared to other dynamic and static bioreactors, while still maintaining the same levels of early memory cells.

Moreover, stirred tank bioreactors are associated with a relatively small footprint and can be readily assimilated, both physically and digitally, into closed and automated workflows. The CTS Dynacellect and stirred tank bioreactors, therefore, represent closed, automated, and scalable building blocks toward a cell therapy manufacturing process that can mitigate the overarching current and future challenges in safety and cost.

• The advantages of a closed, automated cell isolation and bead removal system
• What instrumentation can help you scale up to meet the needs this the cell therapy industry requires
• The importance of bioreactor environmental controls

Evan Zynda PhD

Staff Scientist, Cell Biology at Thermo Fisher Scientific

Dr. Evan Zynda has been with Thermo Fisher Scientific for almost 5 years. He serves as a Senior Scientist in R&D for the department of Cell Culture and Cellular Medicine and has been focused on Cell Therapy process development and product development. He first began studying T cell biology in 2005 at Roswell Park Cancer Institute, where he received a Ph.D. in Molecular and Cellular Biophysics and Biochemistry. During his academic years, he elucidated mechanisms by which tumor cells evade the immune system and went on to apply this knowledge in drug development and cell therapy manufacturing.

Watch now

SPEAKERS

Evan Zynda PhD

Staff Scientist, Cell Biology at Thermo Fisher Scientific

You might also like

Improving cell therapy manufacturing with on-line monitoring of critical process parameters during cell expansion

Boris Aleynik, Mindy Miller

16 July

Watch

Maximizing process control and efficiency in CAR-T cell manufacturing

J Isaacson, M Ahmadi, R Jarres et al.

25 April

Watch

Enhancing CAR-T therapy development: harnessing cell selection flexibility

Tamara Laskowski, Nuala Trainor

2 October

Watch

Improving AAV productivity: a technical deep-dive into next-generation solutions for cell and gene therapy applications

Jim Ludtke, Fletcher Malcom

5 December

Watch

Streamlining immune cell therapy manufacturing workflows with single-use cytokines

Gabriella Perell

19 June

Watch